We are live on ! Find out more
AUTL

Autolus Therapeutics
AUTL

71 hedge funds and large institutions have $204M invested in Autolus Therapeutics in 2022 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

11,033% more call options, than puts

Call options by funds: $334K | Put options by funds: $3K

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

93% more capital invested

Capital invested by funds: $106M → $204M (+$98.5M)

92% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 12

40% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 15

10.39% more ownership

Funds ownership: 54.3% → 64.69% (+10%)

8% more funds holding

Funds holding: 66 → 71 (+5)

Holders
71
Holders Change
+5
Holders Change %
+7.58%
% of All Funds
1.14%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
21
Increased
23
Reduced
12
Closed
15
Calls
$334K
Puts
$3K
Net Calls
+$331K
Net Calls Change
+$137K

Top Buyers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
+$37.9M
2
SP
Syncona Portfolio
Guernsey
+$35.4M
3
AC
Armistice Capital
New York
+$25.9M
4
TAM
TFG Asset Management
Cayman Islands
+$13.3M
5
NCM
Nantahala Capital Management
Connecticut
+$6.49M

Top Sellers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
-$1.25M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$961K
3
WP
Woodline Partners
California
-$916K
4
MA
MYDA Advisors
New York
-$214K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$202K
Name Holding Trade Value Shares
Change 		Change in
Stake
ECM
26
ExodusPoint Capital Management
New York
$649K +$347K +137,404 +67%
CCM
27
CAAS Capital Management
New York
$613K +$816K +322,795 New
IC
28
Ikarian Capital
Texas
$494K – – –
EAM
29
Erste Asset Management
Austria
$353K +$190K +75,000 +63%
E
30
Ergoteles
New York
$321K +$428K +169,180 New
HCA
31
Harbor Capital Advisors
Illinois
$276K -$7.94K -3,139 -2%
Cetera Investment Advisers
32
Cetera Investment Advisers
Illinois
$261K +$5.56K +2,200 +2%
Millennium Management
33
Millennium Management
New York
$239K +$118K +46,640 +59%
PFM
34
Privium Fund Management
Netherlands
$205K – – –
LSA
35
Leonteq Securities AG
Switzerland
$190K +$253K +100,000 New
Morgan Stanley
36
Morgan Stanley
New York
$181K +$130K +51,312 +117%
CC
37
Covalis Capital
United Kingdom
$129K +$171K +67,767 New
Geode Capital Management
38
Geode Capital Management
Massachusetts
$102K -$202K -79,702 -60%
State Street
39
State Street
Massachusetts
$102K +$607 +240 +0.5%
Renaissance Technologies
40
Renaissance Technologies
New York
$88K +$53.4K +21,100 +84%
WE
41
Wealth Effects
Massachusetts
$80.3K -$3.41K -1,350 -3%
Two Sigma Investments
42
Two Sigma Investments
New York
$64K +$85.2K +33,700 New
LPL Financial
43
LPL Financial
California
$61.4K +$23K +9,100 +39%
BFM
44
Boothbay Fund Management
New York
$51.7K – – –
Acadian Asset Management
45
Acadian Asset Management
Massachusetts
$40K +$55.7K +22,025 New
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$38.4K +$20.4K +8,063 +66%
AGM
47
Alpine Global Management
New York
$38K +$50.3K +19,885 New
TRCT
48
Tower Research Capital (TRC)
New York
$36K +$31.9K +12,618 +194%
UBS Group
49
UBS Group
Switzerland
$32.3K -$62.6K -24,776 -59%
Osaic Holdings
50
Osaic Holdings
Arizona
$32.2K +$41.5K +16,425 +3,285%
1
2
3 4

AUTL Hedge Fund Activity: Q4 2022 in Review

71 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q4 2022, worth a combined $204M — up 93% from $106M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new AUTL positions and 15 closed out — a net gain of 6 holders — while 23 added to existing stakes and 12 trimmed.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $37.9M. The largest seller was UBS O'Connor, exiting entirely with an estimated $1.25M sold.

  • 71 institutional investors held Autolus Therapeutics (AUTL) as of Q4 2022, up from 66 in Q3 2022.
  • Funds reported $204M of Autolus Therapeutics stock for Q4 2022, up 93% quarter-over-quarter.
  • 21 funds opened new Autolus Therapeutics positions in Q4 2022 and 15 closed out, a net change of +6 holders.
  • The largest Autolus Therapeutics buyer in Q4 2022 was Deep Track Capital, an estimated $37.9M added.
  • The largest Autolus Therapeutics seller in Q4 2022 was UBS O'Connor, an estimated $1.25M sold.

Based on aggregated 13F filings for Q4 2022.